– New investors include Eventide, RTW, Perceptive Advisors, Cowen Healthcare Investments, Cormorant Capital, and Point72 –
-Proceeds to accelerate clinical development of PRA023, a potential best in class TL1A antibody for IBD, and expansion of Prometheus’ 360 platform –
SAN DIEGO, November 9, 2020 /PRNewswire/ — Prometheus Biosciences, Inc. (“Prometheus”), a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD), today announced the completion of a $130 million equity financing led by Eventide Asset Management and RTW Investments, LP. Additional new investors include Perceptive Advisors, Cowen Healthcare Investments, Cormorant Capital, Point72 Asset Management and Irving Investors, with participation from existing investors Ascend Global Investment Fund, Cedars-Sinai Medical Center and Nestlé SA. In connection with the financing, Joy Ghosh, Ph.D. of Eventide Asset Management and Adam Stone of Perceptive Advisors will be joining the Prometheus Board of Directors.
“We are pleased to have the support of such outstanding investors who share our dedication and vision to build the world’s leading precision medicine company for IBD,” said Mark McKenna, President and CEO of Prometheus. “We are now well-positioned to advance the clinical development of our lead antibody program targeting TL1A-associated IBD and grow our emerging pipeline of precision medicine programs designed to deliver life-changing outcomes for patients.”
“The IBD treatment landscape has seen limited innovation to date despite an enormous effort to unlock benefit from traditional therapeutic approaches. Prometheus has the potential to disrupt the space with its precision medicine approach as well as its genotype-phenotype Prometheus 360 drug discovery platform designed to create novel IBD medicines to benefit patients,” said Joy Ghosh, Ph.D. of Eventide Asset Management.
About Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc. is a privately held biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company’s precision medicine platform, Prometheus 360, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is guided by its board of directors, led by Chairman Tachi Yamada, M.D., and a scientific advisory board composed of key opinion leaders in IBD, including Stephan Targan, M.D., William Sandborn, M.D. and Dermot P. McGovern, M.D., Ph.D. In addition, Prometheus has entered into collaborations to develop targeted therapies for IBD.
Prometheus maintains its headquarters in San Diego, CA. For more information about Prometheus, please visit www.prometheusbiosciences.com.
Investor Relations and Media Contact
Amy Conrad, (858) 914-1962